Stay updated on Anti-PD-1 Monoclonal Antibody Clinical Trial

Sign up to get notified when there's something new on the Anti-PD-1 Monoclonal Antibody Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anti-PD-1 Monoclonal Antibody Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the safety, tolerability, pharmacokinetics, and preliminary antitumor activities of the Anti-PD-1 monoclonal antibody BGB-A317 in Chinese patients with advanced solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:22.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as confirmed advanced or metastatic tumors, measurable lesions, and adequate organ function, among others. Previously, this section had no information provided.
    Difference
    31%
    Check dated 2024-05-22T21:22:50.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:34:52.000Z thumbnail image

Stay in the know with updates to Anti-PD-1 Monoclonal Antibody Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anti-PD-1 Monoclonal Antibody Clinical Trial page.